TRVI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 22:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Dagens volum	64 935.00
Gjennomsnittsvolum	256 709
Markedsverdi	195.11M
EPS	$0 ( 2024-05-09 )
Neste inntjeningsdato	( $-0.110 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.15
ATR14	$0.0120 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-10	Good Jennifer L	Buy	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Stock Option (right to buy)
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)

INSIDER POWER
79.66
Last 98 transactions
Buy: 24 441 332 \| Sell: 1 388 191

Volum Korrelasjon

Lang: 0.13 (neutral)

Kort: -0.54 (weak negative)

Signal:(42.223) Neutral

Trevi Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Trevi Therapeutics Inc Korrelasjon - Valuta/Råvare

0.49
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.58
( weak )

-0.55
( weak negative )

-0.39
( neutral )

Trevi Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
Omsetning:	$0
Bruttogevinst:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
Omsetning:	$0
Bruttogevinst:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.